Market Newsdesk

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — National shareholder rights firm Hagens Berman is investigating claims alleged in a pending securities class action suit against Roblox Corporation (NYSE: RBLX) and its management following disclosures that the company’s age verification rollout caused significant, undisclosed friction to its user growth and platform engagement.

SUBMIT YOUR RBLX LOSSES TO HBSS NOW

The firm’s investigation focuses on the suit’s claims that Defendants misled investors regarding the operational consequences of the safety-focused initiatives the company had purportedly implemented.

Allegations Concerning Age Verification and Growth:

The suit follows a sharp decline in Roblox’s share price on May 1, 2026, after the company reported its Q1 2026 financial results. The core allegations, which have emerged in recently filed complaint against the company, contend that Roblox failed to disclose that its age-check rollout:

• Reduced Platform Engagement: The age verification features hindered on-platform communication, leading to a decline in user interaction.
• Negatively Impacted Organic Growth: The friction caused by these features resulted in lower app store ratings and a corresponding reduction in organic user sign-ups.
• Misrepresented Growth Potential: Throughout the class period (October 30, 2025 – April 30, 2026), Roblox characterized the rollout as a “gold standard” implementation while allegedly knowing it would lead to a significant slowdown in user growth.

Key Disclosures and Market Impact

• April 30, 2026: Roblox revealed a steep deceleration in year-over-year and sequential DAU growth, slashed its 2026 revenue guidance and severely cut its 2026 bookings growth. The company blamed its dismal results on just 51% of Roblox global DAUs having age checked. The company further revealed that “as a result of age check […] we have seen a reduction in app store ratings, and we believe this may be contributing to a reduction in organic sign-ups that typically flow from app stores.” Roblox also said its lowered prospects are the result of “continued friction” resulting from the age-check rollout.
• Market Correction: The news caused Roblox shares to fall $10.13, or approximately 18.33%, on May 1, 2026, erasing over $6.7 billion in market capitalization.

Hagens Berman’s Investigation

“We’re focused on when Roblox and its management knew of the adverse consequences of the age-check rollout and whether they intentionally misled investors about it,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Investor Rights and Lead Plaintiff Deadline

Hagens Berman is currently evaluating the claims alleged in the suit brought on behalf of a putative class of investors who purchased Roblox securities between October 30, 2025, and April 30, 2026. If you suffered financial losses on RBLX during the class period, you are encouraged to contact our office to learn more about your legal rights and the ongoing class action litigation. The court-imposed deadline to move for appointment as lead plaintiff is August 7, 2026.

• 
  Report your losses now
  
• Contact Our Attorneys:
  
  [email protected]
  
• Investor Hotline: 844-916-0895
• Hagens Berman’s Roblox Page:
  
  www.hbsslaw.com/cases/roblox
  

If you’d like more information and answers to other frequently asked questions about the Roblox case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Roblox should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Embecta Corp. (NASDAQ: EMBC) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit follows the company’s disastrous Q2 2026 earnings report, apparently at odds with prior narrative, which triggered a massive selloff in the stock and analysts’ questions.

These developments have prompted national shareholder rights firm Hagens Berman to open an investigation into claims that Embecta violated the federal securities laws.

The firm encourages Embecta investors who suffered substantial losses to submit your losses now.

Class Period: Nov. 25, 2025 – May 4, 2026
Lead Plaintiff Deadline: Aug. 17, 2026
Visit:www.hbsslaw.com/investor-fraud/embc
Contact the Firm Now: [email protected]
                                       844-916-0895

Embecta Corp. (EMBC) Securities Class Action:

Embecta is a global medical device company whose core business product is pen needles – sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. In the past, pen needle revenues have comprised over 70% of the company’s total revenues.

The litigation’s primary focus is on the propriety of Embecta’s Class Period repeated assurances that “insulin pens have been stable […] showing the underlying resilience and the durability of that portfolio[]” and “our pen needle business is incredibly resolute.” This narrative formed the basis for the company’s February 5, 2026 guidance reiterating 2026 adjusted EPS of $2.80 – $3.00.  The company also touted maintenance of its dividend within its capital allocation plans as a return of capital to shareholders.

The complaint alleges the company’s assurances and guidance were misleading when given because Embecta knew or recklessly disregarded that weaknesses in the pen needle market was likely to significantly disrupt the company’s annual guidance and Q2 results.

On May 5, 2026, investors’ expectations vanished. That day, Embecta reported Q2 2026 adjusted EPS of $0.27, a staggering sequential and year-over-year decline of about 61%. In contrast to the company’s assurances of stability, resilience, and durability, Embecta’s pen needles revenues also suffered massive sequential and year-over-year declines. Of additional concern, Embecta slashed its 2026 adjusted EPS guidance to $1.55 – $1.75, or down roughly 43% at the mid-point, and reduced its dividend by 93% to just $0.01.

In response, the market sent the price of Embecta shares tumbling, with one prominent analyst who downgraded the company highlighting Embecta management’s “need to rebuild investor credibility on commercial execution and the profitability outlook.”

“Our investigation is focused the extent to which and when Embecta and its management knew about pen needle and U.S. business revenue headwinds, and whether they were sufficiently transparent about those risks,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Embecta and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Embecta case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Embecta should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:
Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Hagens Berman (HBSS), a securities litigation leader, is broadening its investigation into Verra Mobility Corp. (NASDAQ: VRRM) following the company’s disclosure of an abrupt leadership transition. The news comes in the wake of a securities action suit stemming from the catastrophic loss of a major contract.

VRRM Investors Submit Your Losses Now to HBSS

Class Period: Feb. 24, 2026 – May 26, 2026
Lead Plaintiff Deadline: Aug. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/vrrm
Contact the Firm Now: [email protected] | 844-916-0895

Leadership Vacuum

On June 1, 2026, Verra Mobility announced that long-time CEO David Roberts has abruptly stepped down, ending a 12-year tenure. This departure follows a volatile period for the company, initiated by the unexpected termination of a key contract with Avis Budget Group—a move that wiped out approximately $1.4 billion in shareholder value.

The Board of Directors has appointed former Chief Transformation and Legal Officer Jon Keyser as interim President and CEO while retaining a global search firm for a permanent replacement. Hagens Berman is investigating whether the departure is causally related to the allegations in the securities class action suit.

Verra Mobility Corporation (VRRM) Securities Class Action:

The complaint alleges Verra made false and misleading statements and did not disclose important information to investors about the true state of the Verra/Avis relationship and the likelihood of Verra receiving an Avis contract renewal.

The truth allegedly emerged on May 26, 2026, when Verra disclosed that it received a termination notice effective September 2026 from Avis regarding the companies’ contract, that it is taking immediate actions to cut costs, adapt operations, and reposition its business, and revised its 2026 outlook that significantly deviated from that given just twenty days prior.

Verra also revealed that it was reviewing the parties’ negotiations and handling of confidential information.

The news promptly sent the price of Verra shares 70% crashing lower on May 27, 2026, amputating $1.4 billion from the company’s market capitalization in a single day.

View our latest video summary of the allegations: youtu.be/FVEw5XACoGA

“Our investigation is focused on the extent to which and when Verra and its executives knew that renegotiations with Avis were far from constructive, as the May 26 surprise reveals,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Verra and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the Verra case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Verra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (NASDAQ: ERAS) faces a securities class action after the stock tanked $9.25 (-48%) on news that Revolution Medicines (RevMed) accused Erasca of patent infringement concerning Erasca’s pan-RAS molecular glue targeting solid tumors (ERAS-0015) and that a patient died one month after receiving ERAS-0015.

The lawsuit seeks to represent investors who purchased or otherwise acquired Erasca common stock between January 14, 2025 and April 26, 2026.

National shareholder rights law firm Hagens Berman is continuing its investigation into legal claims that Erasca violated the federal securities laws and urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights.

Class Period: Jan. 14, 2025 – Apr. 26, 2026
Lead Plaintiff Deadline: Aug. 10, 2026
Visit:www.hbsslaw.com/investor-fraud/eras
Contact the Firm Now:[email protected]
                                       844-916-0895

Erasca, Inc. (ERAS) Securities Class Action:

Precision oncology company Erasca’s ERAS-0015 is the company’s investigational, oral, potentially “best-in-class” pan-RAS molecular glue under development to treat RAS-mutant solid tumors, including pancreatic ductal adenocarcinoma.

The complaint alleges that Erasca favorably compared the equivalence of its ERAS-0015 40 milligram dose cohort to RevMed’s RMC-6236 400 milligram dose cohort. In addition, as recently as March 12, 2026, Erasca allegedly assured investors of its ERAS-0015 intellectual property protection, and touted that its ERAS-0015 has “in-licensed one patent family from Joyo” that “includes one issued US patent, one pending US non-provisional patent application, one issued foreign patent, and thirteen pending foreign patent applications.”

The complaint alleges that Erasca misled the market because, unknown to investors, comparisons of ERAS-0015 to RMC-6236 were improper, exposed the company to intellectual property disputes, and as a result the company’s proffers about ERAS-0015 lacked a reasonable basis.

The truth allegedly emerged on April 27, 2026. That day, Erasca disclosed two important matters concerning the ERAS-0015 “best-in-class” narrative.

First, before the market opened, Erasca disclosed that it received a letter from RevMed’s legal counsel challenging the validity of Erasca’s intellectual property claims. RevMed contends Erasca obtained RevMed’s trade secrets through third-party misappropriation and deceptively compared the competing therapies.

Second, after the market closed, the company revealed that a patient being treated with ERAS-0015 suffered an adverse event, presented to the ER a month after receiving the treatment, and then died.

The market swiftly reacted to these disclosures, sending the price of Erasca shares down $9.25 (-48%) the next day and wiping out over $2.8 billion of Erasca’s market capitalization.

“We’re investigating whether Erasca may have intentionally misled investors about ERAS-0015’s safety profile and about a potential moat in its particular, highly competitive cancer treatment space,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Erasca and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Erasca case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Erasca should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:
Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Hagens Berman (HBSS), a national leader in securities litigation, is actively investigating claims in a securities class action lawsuit against GeneDx Holdings (NASDAQ: WGS) and its executives, alleging defendants misled investors about the Fabric Genomics acquisition and synergy potential.

The suit follows a devastating 49% stock collapse on May 5, 2026 in response to the company’s disastrous Q1 2026 earnings report, including a $31.2 million impairment charge.

The firm urges GeneDx investors who suffered significant losses to contact the firm now.

Class Period: Apr. 16, 2025 – May 4, 2026
Lead Plaintiff Deadline: Aug. 3, 2026
Visit:www.hbsslaw.com/investor-fraud/wgs
Contact the Firm Now:[email protected]
                                       844-916-0895

The GeneDx Securities Class Action: The Fabrics Genomics Discrepancy

The complaint alleges that GeneDx falsely touted the acquisition of Fabric Genomics as a cornerstone of its efficiency and future profitability.

But on May 4, 2026, GeneDx reported dismal Q1 2026 financial results which included a massive tenfold increase in net loss compared to the prior year period. The Fabric Genomics business (which reported a $2.5 million revenue miss) was the largest contributor to the loss, as GeneDx recorded impairment charges related to the unit totaling $31.2 million, or about 94% of the cash paid for it just one year ago.

In addition, GeneDx’s ARR fell about $200 short, a surprise blamed on a huge, adverse change in product mix toward genome whose ARR was only half that of exome. The company also said that exome and genome revenue growth would be “at least 20%,” substantially lower than it said as recently as February. As a result of GeneDx’s changed growth narrative, the company slashed 2026 revenue guidance by 12%.
Leadership Maneuver

In the wake of the stock price cratering, GeneDx recently appointed a new President, Mark Gardner. Hagens Berman is investigating whether this leadership change is causally related to alleged failures that preceded the May collapse.

“The complaint alleges that investors were sold a vision of technological synergy, only to be hit with a massive impairment charge,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation. “We’re investigating whether GeneDx’s leadership knew of a disconnect between their public projections and the internal reality of their acquisitions.”

If you invested in GeneDx and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the GeneDx case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding GeneDx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — On February 20, 2026, GRAIL, Inc. (NASDAQ: GRAL) shed over $2.2 billion of market capitalization after surprising investors with its NHS-Galleri Trial readout. The news caused huge investor losses and triggered a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired shares of GRAIL common stock between May 13, 2025 and February 19, 2026.

National shareholder rights firm Hagens Berman is investigating the alleged claims that GRAIL and its co-defendant executives violated the federal securities laws and encourages GRAIL investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge about GRAIL’s NHS-Galleri Trial to contact the firm’s attorneys.

Class Period: May 13, 2025 – Feb. 19, 2026
Lead Plaintiff Deadline: Aug. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/gral
Contact the Firm Now: [email protected]
                                       844-916-0895

GRAIL, Inc. (GRAL) Securities Class Action:

Commercial stage healthcare company GRAIL focuses on early cancer detection.

The litigation focuses on the propriety of GRAIL’s disclosures about the design of its NHS-Galleri trial (the “trial”) and the likelihood it would meet its primary endpoint – with three consecutive years of follow-up screening, the absolute reduction in the number of late stage (stages 3 and 4) cancer diagnoses.

During the Class Period, GRAIL expressed high confidence in the trial’s design and likely outcomes. They consistently stated that the three-year duration was specifically chosen to demonstrate a statistically significant reduction in combined stage 3 and 4 cancers.

The complaint alleges that GRAIL misled investors by creating the false impression that it possessed reliable information supportive of the probability of the trial achieving its primary endpoint. The complaint further alleges that GRAIL’s expressed optimism was unrealistic because, unknown to investors, the company had information suggesting that three years would be insufficient to support the trial’s achievement of the primary endpoint.

Investors learned the truth on February 19, 2026. That day, the defendants announced that the trial failed to achieve its primary endpoint. Of significant concern was the admission that “we probably should have allowed for a longer follow-up period.”

The market quickly reacted, sending the price of GRAIL shares down over 50% the next day.

“We’re focused on when GRAIL and its management knew that the need for a longer follow-up period diverged from the touted three-year duration,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims in the filed lawsuit.

If you invested in GRAIL and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the GRAIL case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding GRAIL should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Hagens Berman, a recognized leader in securities litigation, is actively investigating claims pled in an investor class action alleging that PicS N.V. (NASDAQ: PICS) January 30, 2026, Initial Public Offering (IPO) documents contained misrepresentations and omissions.

CLICK HERE TO SUBMIT YOUR PICS IPO LOSSES TO HBSS

Lead Plaintiff Deadline: Aug. 4, 2026
Visit:www.hbsslaw.com/investor-fraud/pics
Contact the Firm Now: [email protected]
                                       844-916-0895

PicS N.V. (PICS) Securities Class Action: IPO Disclosure vs. Internal Reality

The PICS securities class action focuses on the propriety of PicS’ disclosures concerning the sufficiency of its credit evaluation procedures, allowance for expected credit losses (“ECL”), and classification of financial assets into Stage 1 (no significant increase in credit risk since recognition), Stage 2 (significant increase in credit risk subsequent to recognition) and Stage 3 (credit impaired).

The complaint alleges that, unknown to investors, PicS had evaluated its credit evaluation procedures before the IPO. During December 2025, PicS determined they were deficient and required enhancement.

In addition, the complaint alleges that PicS’ enhancement procedures resulted in the company reclassifying approximately R$590 million of exposures from Stage 2 to Stage 3 and resulted in an incremental ECL charge of R$88 million in the three months ended December 31, 2025.

Moreover, the complaint alleges PicS experienced a heightened and undisclosed Stage 3 formation rate showing new contracts entering default spiking from 3.8% in Q3 2025 to over 7% in Q4 2025. The metric substantially deviated from the results and trends disclosed in the IPO offering documents.

On March 19, 2026, PicS filed its financial results for its Q4 and FY 2025, which both ended before the IPO. The company’s Stage 2 to Stage 3 reclassifications as well as its spike in defaulting Stage 3 loans were among the matters revealed in the filing.

Then, on June 2, 2026, PicS announced its Q1 2026 results revealing significant additional deterioration in credit quality and a massive 13% spike in Stage 3 loans.

“We’re focused on whether PicS’ IPO documents were negligently prepared for failing to disclose adverse facts about its credit evaluation processes,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in PicS and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the PicS case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding PicS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:
Reed Kathrein, 844-916-0895

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — National shareholder rights firm Hagens Berman (HBSS) is actively investigating claims alleged against Veritone, Inc. (NASDAQ: VERI) and certain of its executives in a pending securities class action filed after the company admitted its previously issued financial statements were materially misstated.

SUBMIT YOUR VERI LOSSES TO HBSS

The firm’s investigation focuses on the suit’s claims that Veritone and its management violated the securities laws by intentionally misleading investors regarding the company’s financial performance through improper accounting practices during the period from October 14, 2025, to April 14, 2026.                                   

Allegations of Improper Accounting and Revenue Inflation:

The securities class action follows a series of disclosures in early 2026 that resulted in significant declines in Veritone’s share price. The core allegations, which emerged in a recently filed complaint against the company, claim that Veritone failed to disclose that it:

• Inaccurately recorded and/or misclassified certain revenue and costs. 
• Overstated its revenue, assets, accounts receivable, royalties, and other comprehensive income. 
• Maintained deficient internal controls over accounting and financial reporting. 
• Provided investors with positive statements regarding its business, operations, and prospects that lacked a reasonable basis.

Key Disclosures and Market Impact

• March 26, 2026: Veritone announced that it was “finalizing its accounting determination of certain revenue transactions,” causing shares to fall over 29% the following day.
• April 1, 2026: The company delayed its annual report filing due to accounting determination issues regarding barter revenue, leading to another stock decline. 
• April 14, 2026: Veritone formally disclosed that its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025, should no longer be relied upon, citing errors in software valuation and revenue misclassification, which drove the price of Veritone shares down further.

Hagens Berman’s Investigation

“Our investigation is focused on whether Veritone and its management intentionally misled investors about its financial performance using now-admitted improper accounting,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Investor Rights and Court Deadlines

If you invested in Veritone securities during the Class Period (October 14, 2025 – April 14, 2026) and suffered financial losses, you may be eligible to serve as lead plaintiff in the ongoing litigation. The court-imposed deadline to move for appointment as lead plaintiff is July 20, 2026.

• 
  Report your losses
  
• Contact the Firm Now:
  
  [email protected]
  
• HBSS Investor Hotline: 844-916-0895
• Hagens Berman Veritone Site:
  www.hbsslaw.com/cases/veritone

View our latest video summary of the allegations: youtu.be/dflmz_R1g64

Whistleblowers: Persons with non-public information regarding Veritone should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895

DODGEVILLE, Wis., July 13, 2026 (GLOBE NEWSWIRE) — Lands’ End, Inc. (Nasdaq: LE) today reported that it made the following inducement grants to Charlie Cole on July 13, 2026, in connection with his commencement of employment and appointment as Chief Executive Officer. The grants were not made under a shareholder approved equity plan and were previously described in a Current Report on Form 8-K filed by Lands’ End with the Securities and Exchange Commission on June 30, 2026.

Mr. Cole’s inducement grants consist of an inducement sign-on grant of 109,361 restricted stock units, payable in the form of shares of Lands’ End, Inc. common stock (“Common Stock”), and an inducement sign-on grant of options to purchase up to 166,018 shares of Common Stock at an exercise price equal to $11.43 per share, which in each case will vest 25%, 25% and 50% per year, on, respectively, the first three anniversaries of Mr. Cole’s July 13, 2026 start date, subject to his satisfaction of vesting conditions.

About Lands’ End, Inc.

Lands’ End, Inc. (NASDAQ:LE) is a leading digital retailer of solution-based apparel, swimwear, outerwear, accessories, footwear, home products and uniforms. Lands’ End offers products online at www.landsend.com, through third-party distribution channels and our own Company Operated stores. Lands’ End also offers products to businesses and schools, for their employees and students, through the Outfitters distribution channel. Lands’ End is a classic American lifestyle brand that creates solutions for life’s every journey.

CONTACTS

Lands’ End, Inc.
Bernard McCracken
Chief Financial Officer
(608) 935-4100

Investor Relations:
ICR, Inc.
Tom Filandro
(646) 277-1235
[email protected]

SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP (HBSS), a leading national securities litigation firm, is investigating claims in a securities class action lawsuit against Sportradar Group (NASDAQ: SRAD) and its executives.  The lawsuit is brought on behalf of investors who purchased or otherwise acquired Sportradar Class A ordinary shares between November 7, 2024 and April 21, 2026, and suffered financial losses.

The lawsuit follows the dramatic 22% single day collapse in SRAD stock price on April 22, 2026, triggered by damaging investigative reports from Muddy Waters Research and Callisto Research.  These reports accused the company of deceiving investors about the legality of its core business model and true sources of its revenue.

Hagens Berman is actively investigating the claims that Sportradar violated federal securities laws. Investors who lost money on Sportradar stock (SRAD) are encouraged to submit your losses now to learn about their legal options and potential recovery. Individuals with insider knowledge or information relevant to the Hagens Berman investigation are also urged to contact the firm’s attorneys.

View our latest video summary of the allegations: youtu.be/90cf7_368dk

Class Period: Nov. 7, 2024 – Apr. 21, 2026
Lead Plaintiff Deadline: July 17, 2026
Visit:www.hbsslaw.com/investor-fraud/srad
Contact the Firm Now: [email protected]
                                        844-916-0895

What is the Sportradar Group AG (SRAD) Securities Class Action About?

The class action lawsuit alleges that Sportradar misrepresented and concealed that the company deliberately partnered with black-market unlicensed gambling operators to inflate its revenues, despite publicly touting strict legal and regulatory compliance and claiming that ethics and integrity were foundational to the company’s operations.

Investors’ confidence in Sportradar’s business practices, including its purported KYC and Code of Conduct, was shattered on April 22, 2026, when two prominent short seller firms published detailed investigative reports that directly contradicted Sportradar’s prior statements about compliance and corporate governance.

Muddy Waters Research conducted an undercover investigation, analyzed Sportradar’s website code, and interviewed 15 current and former company employees to reach its conclusion that “SRAD has actively aided and abetted illegal gambling across the world’s black and grey markets – not as an accident or an oversight, but as a business strategy.” The firm “estimate[d] that illegal operators today deliver approximately 20-40% of total revenues[]” to Sportradar. Muddy Waters said it “identified nearly 50 companies as current or recent SRAD clients and collaborators who are operating in illegal markets.”

For its part, Callisto examined hundreds of gambling platforms and reported that it found evidence that “over 270 individual platforms (more than a third of the 800 Sportradar claims to serve) are using Sportradar’s products or services, or explicitly claiming to do so, while operating illegally in regulated or prohibited gambling markets.” Callisto also said “[m]any of these operators have no license whatsoever[]” and “a senior former employee we spoke to estimated the exposure to unlicensed operators could be as high as 30-40% of Sportradar’s revenue.”

The market swiftly reacted, wiping out over $800 million of Sportradar’s market capitalization in a single day.

“Hagens Berman is investigating the lawsuit’s claims that Sportradar concealed an illegal business strategy from investors and may have booked revenues derived from unlawful gambling operations,” said Reed Kathrein, the Hagens Berman partner leading the firm’s Sportradar securities fraud investigation.

If you are a Sportradar (SRAD) investor who suffered substantial losses, or if you have information that could assist Hagens Berman’s investigation, contact the firm now.

For information about the Sportradar class action lawsuit and and answers to frequently asked questions, read more »

Whistleblowers: Persons with non-public information regarding Sportradar should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:
Reed Kathrein, 844-916-0895